Drugs for Soft-Tissue Sarcoma/Tenosynovial Giant-Cell Tumor
Find financial assistance programs available for soft-tissue sarcoma drugs.
Drug company: Daiichi-Sankyo
Turalio is a kinase inhibitor used for the treatment of adults with symptomatic tenosynovial giant-cell tumor, a type of soft-tissue cancer, that is associated with severe illness or functional limitations and is not amenable to improvement with surgery.
Daiichi-Sankyo offers 2 financial assistance programs for patients who have been prescribed Turalio:
Turalio Copay Program
Patients with private insurance pay as little as $0 per prescription of Turalio, with a maximum annual benefit of $25,000. There are no income requirements for eligibility.
Turalio Patient Assistance Program
Through this program, patients who are uninsured, underinsured, or unable to afford out-of-pocket costs may be eligible to receive Turalio at no cost.
Drug company: Novartis
Votrient is a kinase inhibitor used for the treatment of patients with advanced soft-tissue sarcoma.
Novartis Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Votrient:
Novartis Oncology Universal Co-pay Program
Through this program, patients with private insurance will be responsible for up to the first $25 in copay and co-insurance. The program pays the remaining balance until a yearly maximum of $15,000 is met.
Novartis Patient Assistance Foundation
To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Votrient for free until a prescription drug coverage becomes available to them.
Drug company: Janssen
Yondelis is an alkylating drug used for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma—rare types of soft-tissue sarcoma—after an anthracycline-containing regimen.
Janssen offers 2 financial assistance programs for patients using Yondelis:
Janssen CarePath Savings Program
With this program, privately insured patients may pay only $5 per infusion, with a maximum yearly benefit of $20,000.
Johnson & Johnson Patient Assistance Foundation
This program provides Yondelis free of cost to patients who meet certain financial limits and are either uninsured, underinsured, or enrolled in Medicare Part D.
Table. Drugs Prescribed for SARCOMA/Tenosynovial Giant-Cell Tumor
- Drug name (generic name)
- Drug company
- Patient support services
Last modified: April 1, 2022